본문 바로가기
KERD
논문KCI 등재

Efficacy and Tolerability of Peginterferon Alpha Plus Ribavirin in the Routine Daily Treatment of Chronic Hepatitis C Patients in Korea: A Multi-Center, Retrospective Observational Study

김영석|정재연|이진우|황성규|김연수|임형준|양진모|이준성|김진홍|조성원|장정원|임규성|손주현|Young Min Park|주영수|Chun Kyon Lee|Ju Hyun Kim|정숙향|박충기|박상훈
거트앤리버 소화기연관학회협의회|2012.01|Gut and Liver|제6권 제1호|pp. 98-106

2

조회

0

다운로드

13

인용

0

참고문헌

키워드

KoreanRibavirinChronic hepatitis CPegylated interferon alpha

초록

Background/Aims: We aimed to evaluate the effi cacy and safety of peginterferon plus ribavirin for chronic hepatitis C (CHC) patients under real life setting in Korea. Methods: We retrospectively analyzed the medical records of 758 CHC patients treated with peginterferon plus ribavirin between 2000 and 2008 from 14 university hospitals in the Gyeonggi-Incheon area in Korea. Results: Hepatitis C virus (HCV) genotype 1 was detected in 61.2% of patients, while genotype 2was detected in 35.5%. Baseline HCV RNA level was ≥6×105IU/mL in 51.6% of patients. The sustained virological response (SVR) rate was 59.6% regardless of genotype; 53.6%in genotype 1 and 71.4% in genotype 2/3. On multivariate analysis, male gender (p=0.011), early virological response (p<0.001), genotype 2/3 (p<0.001), HCV RNA <6×105 IU/mL (p=0.005) and adherence to the drug >80% of the planned dose (p<0.001) were associated with SVR. The rate of premature discontinuation was 35.7%. The main reason for withdrawal was intolerance to the drug due to common adverse events or cytopenia (48.2%). Conclusions: Our data suggest that the effi cacy of peginterferon and ribavirin therapy in Koreans is better in Koreans than in Caucasians for the treatment of CHC, corroborating previous studies that have shown the superior therapeutic effi cacy of this regimen Correspondence to: Choong Kee Park Department of Internal Medicine, Hallym University Sacred Heart Hospital, 896 Pyeongchon-dong, Dongan-gu, Anyang 431-070, Korea Tel: +82-31-380-3710, Fax: +82-31-386-2269, E-mail: cpk@hallym.or.kr Received on September 16, 2011. Accepted on Octorber 28, 2011. pISSN 1976-2283 eISSN 2005-1212 http://dx.doi.org/10.5009/gnl.2012.6.1.98This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. in Asians.

Abstract

Background/Aims: We aimed to evaluate the effi cacy and safety of peginterferon plus ribavirin for chronic hepatitis C (CHC) patients under real life setting in Korea. Methods: We retrospectively analyzed the medical records of 758 CHC patients treated with peginterferon plus ribavirin between 2000 and 2008 from 14 university hospitals in the Gyeonggi-Incheon area in Korea. Results: Hepatitis C virus (HCV) genotype 1 was detected in 61.2% of patients, while genotype 2was detected in 35.5%. Baseline HCV RNA level was ≥6×105IU/mL in 51.6% of patients. The sustained virological response (SVR) rate was 59.6% regardless of genotype; 53.6%in genotype 1 and 71.4% in genotype 2/3. On multivariate analysis, male gender (p=0.011), early virological response (p<0.001), genotype 2/3 (p<0.001), HCV RNA <6×105 IU/mL (p=0.005) and adherence to the drug >80% of the planned dose (p<0.001) were associated with SVR. The rate of premature discontinuation was 35.7%. The main reason for withdrawal was intolerance to the drug due to common adverse events or cytopenia (48.2%). Conclusions: Our data suggest that the effi cacy of peginterferon and ribavirin therapy in Koreans is better in Koreans than in Caucasians for the treatment of CHC, corroborating previous studies that have shown the superior therapeutic effi cacy of this regimen Correspondence to: Choong Kee Park Department of Internal Medicine, Hallym University Sacred Heart Hospital, 896 Pyeongchon-dong, Dongan-gu, Anyang 431-070, Korea Tel: +82-31-380-3710, Fax: +82-31-386-2269, E-mail: cpk@hallym.or.kr Received on September 16, 2011. Accepted on Octorber 28, 2011. pISSN 1976-2283 eISSN 2005-1212 http://dx.doi.org/10.5009/gnl.2012.6.1.98This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. in Asians.

참고문헌 (38)

  1. Ghany MG, "Diagnosis, management, and treatment of hepatitis C: an update", Hepatology, 49, pp.1335~1374 (2009)
  2. Suh DJ, "Current status of hepatitis C virus infection in Korea", Intervirology, 49, pp.70~75 (2006)
  3. Lim YS, "Current status of liver disease in Korea: hepatitis C", Korean J Hepatol, 15(Suppl 6), pp.S25~S28 (2009)
  4. Manns MP, "Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial", Lancet, 358, pp.958~965 (2001)
  5. Fried MW, "Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection", N Engl J Med, 347, pp.975~982 (2002)
  6. Hadziyannis SJ, "Peginterferonalpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose", Ann Intern Med, 140, pp.346~355 (2004)
  7. The Korean Association for the Study of the Liver, "Practice guideline for management of hepatitis C", Korean J Hepatol, 10(Suppl), pp.S101~S125 (2004)
  8. Rumi MG, "Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C", Gastroenterology, 138, pp.108~115 (2010)
  9. Ascione A, "Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection", Gastroenterology, 138, pp.116~122 (2010)
  10. 이혁, "우리나라 만성 C형간염의 초치료를 위한 페그인터페론과 리바비린 병합요법", Clinical and Molecular Hepatology, 12(2006), pp.31~40 (2006), 대한간학회
  11. 윤현아, "만성 C형간염에서 페그인터페론과 리바비린 병합요법의 효과", Clinical and Molecular Hepatology, 14(1), pp.36~45 (2008), 대한간학회
  12. 강명주, "우리나라 만성 C형간염 환자에서 페그인터페론과 리바비린의 병합치료에 대한 효과", Clinical and Molecular Hepatology, 14(3), pp.318~330 (2008), 대한간학회
  13. Sinn DH, "Efficacy of peg-interferon-α-2a plus ribavirin for patients aged 60 years and older with chronic hepatitis C in Korea", J Gastroenterol Hepatol, 26, pp.469~476 (2011)
  14. Yu E, "Histologic grading and staging of chronic hepatitis: on the basis of standardized guideline proposed by the Korean Study Group for the Pathology of Digestive Diseases", Korean J Hepatol, 9, pp.42~46 (2003)
  15. YoungSunKim, "The Prognosis of Liver Cirrhosis in Recent Years in Korea", Journal of Korean Medical Science, 18(6), pp.833~841 (2003), 대한의학회
  16. Chae HB, "Current status of liver diseases in Korea: hepatitis B", Korean J Hepatol, 15(Suppl 6), pp.S13~S24 (2009)
  17. "Disease web statistics system for chronic hepatitis C" (2011)[URL]
  18. Seeff LB, "Natural history of chronic hepatitis C", Hepatology, 36(5 Suppl 1), pp.S35~S46 (2002)
  19. Liang TJ, "Pathogenesis, natural history, treatment, and prevention of hepatitis C", Ann Intern Med, 132, pp.296~305 (2000)
  20. Fattovich G, "Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients", Gastroenterology, 112, pp.463~472 (1997)
  21. Sinn DH, "Disease progression and the risk factor analysis for chronic hepatitis C", Liver Int, 28, pp.1363~1369 (2008)
  22. Jang JY, "New treatments for chronic hepatitis C", Korean J Hepatol, 16, pp.263~277 (2010)
  23. McHutchison JG, "Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection", N Engl J Med, 361, pp.580~593 (2009)
  24. Backus LI, "Predictors of response of US veterans to treatment for the hepatitis C virus", Hepatology, 46, pp.37~47 (2007)
  25. Mauss S, "Estimating the likelihood of sustained virological response in chronic hepatitis C therapy", J Viral Hepat, 18, pp.e81~e90 (2011)
  26. Missiha S, "Canadian Pegasys Expanded Access Group. Impact of asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C", Am J Gastroenterol, 102, pp.2181~2188 (2007)
  27. 정은욱, "유전자 2형인 만성 C형간염 환자에서 페그인터페론과 리바비린의 단기간 치료 효과", Clinical and Molecular Hepatology, 13(3), pp.341~348 (2007), 대한간학회
  28. 이헌주, "한국인 만성 C형간염에서 페그인터페론 알파와 리바비린 또는 인터페론 알파와 리바비린의 병합요법: 치료기간에 따른 성적 비교", Clinical and Molecular Hepatology, 14(1), pp.46~57 (2008), 대한간학회
  29. Lee DS, "Outcome of combination therapy of pegylated inerferone with ribavirin in chronic hepatitis C: single center study", Korean J Hepatol, 15(Suppl 3), pp.S134~ (2009)
  30. Song YJ, "Tailored therapy for treatmentnaive chronic hepatitis C with pegylated interferon-alpha and ribavirin: real practice experience", Korean J Hepatol, 16(Suppl 3), pp.S57~ (2010)
  31. Ge D, "Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance", Nature, 461, pp.399~401 (2009)
  32. Suppiah V, "IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy", Nat Genet, 41, pp.1100~1104 (2009)
  33. Tanaka Y, "Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C", Nat Genet, 41, pp.1105~1109 (2009)
  34. 이승태, "Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in Asian patients", JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 26(9), pp.1374~1379, WILEY-BLACKWELL
  35. Jensen DM, "Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)", ribavirin therapy, 2006, pp.43, 954~960
  36. Ferenci P, "Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)", ribavirin, 2005, pp.43, 425~433
  37. Shiffman ML, "Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3", N Engl J Med, 357, pp.124~134 (2007)
  38. Davis GL, "Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C", Hepatology, 38, pp.645~652 (2003)

관련 논문AI추천

우리나라 만성 C형간염 환자에서 페그인터페론과 리바비린의 병합치료에 대한 효과강명주, 김지현, 박상원, 박성재, 박은택, 설상영, 이상혁, 이연재, 정은욱, 최바울대한간학회 · Clinical and Molecular Hepatology2008 · 제14권 제3호Pegylated Interferon and Ribavirin in the Retreatment of Chronic Hepatitis C in Korea고광철, 곽금연, 백승운, 백용한, 유병철, 이준혁, 조현진, 최문석거트앤리버 소화기연관학회협의회 · Gut and Liver2013 · 제7권 제5호High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice김강모, 백승운, 변관수, 서동진, 윤승규, 이관식, 이영상, 이한주, 임영석, 한광협, Nae Yun Heo대한간학회 · Clinical and Molecular Hepatology2013 · 제19권 제1호Treatment Response and Long-Term Outcome of Peginterferon α and Ribavirin Therapy in Korean Patients with Chronic Hepatitis C임선영, 최혁순, Chang Ho Jung, Hoon Jai Chun, Hyung Joon Yim, Sang Jun Suh, Soon Ho Um, Tae Hyung Kim, Yeon Seok Seo거트앤리버 소화기연관학회협의회 · Gut and Liver2016 · 제10권 제5호한국인 만성 C형간염에서 페그인터페론 알파와 리바비린 또는 인터페론 알파와 리바비린의 병합요법: 치료기간에 따른 성적 비교김경옥, 문희정, 은종렬, 이헌주, 최재원대한간학회 · Clinical and Molecular Hepatology2008 · 제14권 제1호Efficacy of peginterferon and ribavirin is associated with the IL28B gene in Korean patients with chronic hepatitis C권오상, 김윤수, 김종우, 김주현, 박상진, 양재원, 정석후, 정영걸, 최덕주대한간학회 · Clinical and Molecular Hepatology2012 · 제18권 제4호

이 간행물의 다른 논문 (21건)

Recent Advances in Noncardiac Chest Pain in Korea김정환, 이풍렬pp. 1-9Gut Hormones and Appetite Control: A Focus on PYY and GLP-1 as Therapeutic Targets in ObesityAkila De Silva, Stephen R. Bloompp. 10-20Evolutionary History of the Helicobacter pylori Genome: Implications for Gastric CarcinogenesisM. Blanca Piazuelo, Pelayo Correapp. 21-28The Biology of Cancer Stem Cells and Its Clinical Implication in Hepatocellular Carcinoma윤승규pp. 29-40Effi cacy of the Combination of Tetracycline, Amoxicillin, and Lansoprazole in the Eradication of Helicobacter pylori in Treatment-Naïve Patients and in Patients Who Are Not Responsive to Clarithromycin-Based Regimens: A Pilot StudyNuriye Ulu, Ayşe Oya Övünç Kurdaş, Fatih Güzelbulut, Züleyha Akkan Çetinkaya, Atakan Yeşil, Mesut Sezikli, Mustafa Erhan Altınözpp. 41-44
원문 보기